Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine 2008 - 2011
  • Residency, Medicine, University of Washington 2005 - 2008
  • M.D., University of Chicago 2005
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2011 - 2013
  • Instructor Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2011
• Research
• 

  Selected Grants

  • Nektar awarded by Nektar Therapeutics 2018 - 2023
  • AbbVie M14-064 awarded by AbbVie Inc. 2018 - 2023
  • AbbVie M16-438 awarded by AbbVie Inc. 2018 - 2023
  • Seattle Genetics-SGN2FF001: A Phase 1, multicenter, open-label, dose-escalation study awarded by Seattle Genetics, Inc 2017 - 2022
  • A Multicenter, phase I open-label dose escalation study of ABBV-085 an antibody drug conjugated in subjects with advanced solid tumors. awarded by AbbVie Inc. 2016 - 2021
  • A Phase 3 Randomized double blined placebo controlled study to evaluate the efficacy and safety of GS-5745 conbimed with mFOLFAX6 as first line treatment in patients with advanced gastric or gastroeso awarded by Gilead Sciences, Inc. 2016 - 2021
  • Phase Ib study of Atezolizumab in combination with Bevacizumab in solid tumor patients awarded by Genentech, Inc. 2017 - 2021
  • A phase I open label dose escalation and dose-expansion study to evaluate the safety toloerability pharmcokinetics immunogenicity and antitumor activate of Medi-9447 alone and in combination with MEDI awarded by MedImmune, Inc. 2015 - 2020
  • A phase 1 first in human open labe dose escalation study of MGD007 a humanized gpA33 x CD3 dual affinity retargeted awarded by MacroGenics, Inc. 2014 - 2019
  • A Multicenter phase 1/1b open label dose escalation study of ABT-165 a dual variable domain immunoglobin in subject with awarded by AbbVie Inc. 2013 - 2019
  • Mountaineer-Phase ll (ACCRU) awarded by Academic and Community Cancer Research United 2017 - 2019
  • A two part phase I multicenter ipen label study of DKN-01 in combination with weekly paclitaxel; Arm A; A dose awarded by Leap Therapeutics, Inc. 2014 - 2019
  • Cabozantinib (XL184) with panitumamab in KRAS wild-type metastatic colorectal cancer with pharmacodynamic studies, XL184 awarded by Exelixis, Inc 2014 - 2019
  • A Multicenter Phase I/Ib open label dose escalation study of ABBV-399, and antibody drug conjugate, in subjects with adv awarded by AbbVie Inc. 2014 - 2019
  • BP29541 awarded by F. Hoffmann-La Roche Ltd 2018
  • A randomized double blinded placebo controlled phase III study of adjuvant Regorafenib versus awarded by Bayer Healthcare Pharmaceuticals Inc 2013 - 2018
  • A Phase ia/b dose escalation study of the safety pharmacokinetics and pharmacodynamics of OMP-131-R10 in advanced solid tumors and in combination awarded by OncoMed Pharmaceuticals 2016 - 2018
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Parseghian, CM, Loree, JM, Morris, VK, Liu, X, Clifton, KK, Napolitano, S, Henry, JT, Pereira, AA, Vilar, E, Johnson, B, Kee, B, Raghav, K, Dasari, A, Wu, J, Garg, N, Raymond, VM, Banks, KC, Talasaz, AA, Lanman, RB, Strickler, JH, Hong, DS, Corcoran, RB, Overman, MJ, and Kopetz, S. "Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-challenge." Annals of Oncology : Official Journal of the European Society for Medical Oncology (November 21, 2018).  Full Text
    • Bekaii-Saab, T, Kim, R, Kim, TW, O'Connor, JM, Strickler, JH, Malka, D, Sartore-Bianchi, A, Bi, F, Yamaguchi, K, Yoshino, T, and Prager, GW. "Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice." Clinical Colorectal Cancer (November 16, 2018). (Review)  Full Text
    • Graham, CN, Christodoulopoulou, A, Knox, HN, Sabatelli, L, Hechmati, G, Garawin, T, and Strickler, JH. "A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US." Journal of Medical Economics 21, no. 11 (November 2018): 1075-1083.  Full Text
    • Strickler, JH, Weekes, CD, Nemunaitis, J, Ramanathan, RK, Heist, RS, Morgensztern, D, Angevin, E, Bauer, TM, Yue, H, Motwani, M, Parikh, A, Reilly, EB, Afar, D, Naumovski, L, and Kelly, K. "First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36, no. 33 (November 2018): 3298-3306.  Full Text
    • Strickler, JH. "EGFR Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance?." Cancer Discovery 8, no. 6 (June 2018): 679-681.  Full Text
    • Strickler, JH, Loree, JM, Ahronian, LG, Parikh, AR, Niedzwiecki, D, Pereira, AAL, McKinney, M, Korn, WM, Atreya, CE, Banks, KC, Nagy, RJ, Meric-Bernstam, F, Lanman, RB, Talasaz, A, Tsigelny, IF, Corcoran, RB, and Kopetz, S. "Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer." Cancer Discovery 8, no. 2 (February 2018): 164-173.  Full Text
    • Jia, J, Morse, MA, Nagy, RJ, Lanman, RB, and Strickler, JH. "Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer." Frontiers in Oncology 8 (January 2018): 305-null.  Full Text
    • Tachibana, M, Papadopoulos, KP, Strickler, JH, Puzanov, I, Gajee, R, Wang, Y, and Zahir, H. "Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours." British Journal of Clinical Pharmacology 84, no. 1 (January 2018): 112-121.  Full Text
    • Strickler, JH, Wu, C, and Bekaii-Saab, T. "Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches." Cancer Treatment Reviews 60 (November 2017): 109-119. (Review)  Full Text
    • Zhu, J, and Strickler, JH. "Clinical applications of liquid biopsies in gastrointestinal oncology." Journal of gastrointestinal oncology 7, no. 5 (October 2016): 675-686. (Review)  Full Text  Open Access Copy
    • Balaban, EP, Mangu, PB, Khorana, AA, Shah, MA, Mukherjee, S, Crane, CH, Javle, MM, Eads, JR, Allen, P, Ko, AH, Engebretson, A, Herman, JM, Strickler, JH, Benson, AB, Urba, S, and Yee, NS. "Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34, no. 22 (August 2016): 2654-2668.  Full Text
    • Zhang, T, Boominathan, R, Foulk, B, Rao, C, Kemeny, G, Strickler, JH, Abbruzzese, JL, Harrison, MR, Hsu, DS, Healy, P, Li, J, Pi, C, Prendergast, KM, Hobbs, C, Gemberling, S, George, DJ, Hurwitz, HI, Connelly, M, Garcia-Blanco, MA, and Armstrong, AJ. "Development of a Novel c-MET-Based CTC Detection Platform." Molecular Cancer Research : Mcr 14, no. 6 (June 2016): 539-547.  Full Text  Open Access Copy
    • Roe, MT, Cyr, DD, Eckart, D, Schulte, PJ, Morse, MA, Blackwell, KL, Ready, NE, Zafar, SY, Beaven, AW, Strickler, JH, Onken, JE, Winters, KJ, Houterloot, L, Zamoryakhin, D, Wiviott, SD, White, HD, Prabhakaran, D, Fox, KAA, Armstrong, PW, Ohman, EM, and TRILOGY ACS Investigators, . "Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome." European Heart Journal 37, no. 4 (January 2016): 412-422.  Full Text
    • Zhu, J, Strosberg, JR, Dropkin, E, and Strickler, JH. "Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX." Journal of Gastrointestinal Cancer 46, no. 2 (June 2015): 166-169.  Full Text
    • Hurwitz, HI, Smith, DC, Pitot, HC, Brill, JM, Chugh, R, Rouits, E, Rubin, J, Strickler, J, Vuagniaux, G, Sorensen, JM, and Zanna, C. "Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study." Cancer chemotherapy and pharmacology 75, no. 4 (April 2015): 851-859.  Full Text
    • "Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: Results of a first-in-man study." Cancer Chemotherapy and Pharmacology 75, no. 4 (January 1, 2015): 851-859.  Full Text
    • Rangwala, F, Bendell, JC, Kozloff, MF, Arrowood, CC, Dellinger, A, Meadows, J, Tourt-Uhlig, S, Murphy, J, Meadows, KL, Starr, A, Broderick, S, Brady, JC, Cushman, SM, Morse, MA, Uronis, HE, Hsu, SD, Zafar, SY, Wallace, J, Starodub, AN, Strickler, JH, Pang, H, Nixon, AB, and Hurwitz, HI. "Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors." Investigational New Drugs 32, no. 4 (August 2014): 700-709.  Full Text
    • Strickler, JH, McCall, S, Nixon, AB, Brady, JC, Pang, H, Rushing, C, Cohn, A, Starodub, A, Arrowood, C, Haley, S, Meadows, KL, Morse, MA, Uronis, HE, Blobe, GC, Hsu, SD, Zafar, SY, and Hurwitz, HI. "Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer." Investigational New Drugs 32, no. 2 (April 2014): 330-339.  Full Text
    • Nussbaum, DP, Bhattacharya, SD, Jiang, X, Cardona, DM, Strickler, JH, and Blazer, DG. "Gastroesophageal heterotopia and HER2/neu overexpression in an adenocarcinoma arising from a small bowel duplication." Archives of pathology & laboratory medicine 138, no. 3 (March 2014): 428-431.  Full Text
    • "Palliative treatment of metastatic colorectal cancer: What is the optimal approach? Topical collection on gastrointestinal cancers." Current Oncology Reports 16, no. 1 (January 1, 2014).  Full Text
    • Morse, MA, Uronis, HE, Blobe, GC, Hsu, SD, Zafar, SY, and Hurwitz, HI. "Phase i study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer." Investigational New Drugs 32, no. 2 (January 1, 2014): 330-339.  Full Text
    • Murphy, J, Meadows, KL, Starr, A, Broderick, S, Brady, JC, Cushman, SM, Morse, MA, Uronis, HE, Hsu, SD, Zafar, SY, Wallace, J, Starodub, AN, Strickler, JH, Pang, H, Nixon, AB, and Hurwitz, HI. "Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors." Investigational New Drugs 32, no. 4 (January 1, 2014): 700-709.  Full Text
    • Strickler, JH, and Hurwitz, HI. "Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?." Current Oncology Reports 16, no. 1 (2014): 1-8.
    • Strickler, JH, and Hurwitz, HI. "Palliative treatment of metastatic colorectal cancer: what is the optimal approach?." Current Oncology Reports 16, no. 1 (January 2014): 363-null. (Review)  Full Text
    • Strickler, JH, and Hurwitz, HI. "Palliative treatment of metastatic colorectal cancer: what is the optimal approach?." Current oncology reports 16, no. 1 (2014): 363--.  Full Text
    • Tachibana, M, Papadopoulos, KP, Strickler, J, Puzanov, I, Gajee, R, Wang, Y, and Zahir, H. "Abstract C85: Drug interaction study of tivantinib in cancer subjects using a cocktail approach." Molecular Cancer Therapeutics 12, no. 11_Supplement (November 1, 2013): C85-C85.  Full Text
    • Roe, MT, Armstrong, PW, Fox, KAA, White, HD, Prabhakaran, D, Goodman, SG, Cornel, JH, Bhatt, DL, Clemmensen, P, Martinez, F, Ardissino, D, Nicolau, JC, Boden, WE, Gurbel, PA, Ruzyllo, W, Dalby, AJ, McGuire, DK, Leiva-Pons, JL, Parkhomenko, A, Gottlieb, S, Topacio, GO, Hamm, C, Pavlides, G, Goudev, AR, Oto, A, Tseng, C-D, Merkely, B, Gasparovic, V, Corbalan, R, Cinteză, M, McLendon, RC, Winters, KJ, Brown, EB, Lokhnygina, Y, Aylward, PE, Huber, K, Hochman, JS, Ohman, EM, and TRILOGY ACS Investigators, . "Prasugrel versus clopidogrel for acute coronary syndromes without revascularization." The New England Journal of Medicine 367, no. 14 (October 2012): 1297-1309.  Full Text
    • Strickler, JH, Starodub, AN, Jia, J, Meadows, KL, Nixon, AB, Dellinger, A, Morse, MA, Uronis, HE, Marcom, PK, Zafar, SY, Haley, ST, and Hurwitz, HI. "Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors." Cancer Chemotherapy and Pharmacology 70, no. 2 (August 2012): 251-258.  Full Text
    • Strickler, JH, and Hurwitz, HI. "Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability." The Oncologist 17, no. 1 (January 10, 2012): 9-10.  Full Text
    • Strickler, JH, and Hurwitz, HI. "Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer." The Oncologist 17, no. 4 (January 2012): 513-524. (Review)  Full Text
    • Strickler, JH, Cohn, AL, Arrowood, C, Haley, S, Morse, M, Uronis, H, Blobe, GC, Hsu, SD, Zafar, Y, and Hurwitz, H. "Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer." Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 3586-3586.  Full Text
    • Strickler, JH, Cohn, AL, Arrowood, C, Haley, S, Morse, M, Uronis, H, Blobe, GC, Hsu, SD, Zafar, Y, and Hurwitz, H. "Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 3586-.
    • Kline, J, Brown, IE, Zha, Y-Y, Blank, C, Strickler, J, Wouters, H, Zhang, L, and Gajewski, TF. "Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma." Clinical Cancer Research 14, no. 10 (2008): 3156-3167.  Full Text
    • Coil, DA, Strickler, JH, Rai, SK, and Miller, AD. "Jaagsiekte Sheep Retrovirus Env Protein Stabilizes Retrovirus Vectors against Inactivation by Lung Surfactant, Centrifugation, and Freeze-Thaw Cycling." Journal of Virology 75, no. 18 (September 15, 2001): 8864-8867.  Full Text

  • Conference Papers

    • Turner, MC, Keenan, JE, Rushing, CN, Gulack, BC, Nussbaum, DP, Benrashid, E, Hyslop, T, Strickler, JH, Mantyh, CR, and Migaly, J. "Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response." January 11, 2019.  Full Text
    • Bekaii-Saab, T, Marcello, K, Fisher, G, Kopetz, S, Strickler, J, Venook, A, and Obholz, K. "Variability of current global practice patterns in the management of metastatic colorectal cancer." ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona, SPAIN. June 20, 2018 - June 23, 2018.: OXFORD UNIV PRESS, June 1, 2018.  Link to Item
    • Wainberg, Z, Strickler, J, Gordon, M, Barve, M, Wang, L, Yue, H, Motwani, M, Kasichayanula, S, Naumovski, L, and Hamilton, E. "Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)." ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona, SPAIN. June 20, 2018 - June 23, 2018.: OXFORD UNIV PRESS, June 1, 2018.  Link to Item
    • Wainberg, Z, Wang, L, Yue, H, Motwani, M, Kasichayanula, S, Blaney, M, Naumovski, L, and Strickler, J. "ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress." ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona, SPAIN. June 20, 2018 - June 23, 2018.: OXFORD UNIV PRESS, June 1, 2018.  Link to Item
    • Jia, J, Niedzwiecki, D, Uronis, HE, Morse, M, Zafar, Y, Hsu, SD, Bolch, E, Nagy, RJ, Lanman, RB, Talasaz, A, Haley, S, Nixon, AB, and Strickler, JH. "A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood." : American Society of Clinical Oncology (ASCO), May 20, 2018.  Full Text
    • Berlin, J, Ramanathan, RK, Strickler, JH, Subramaniam, DS, Marshall, J, Kang, Y-K, Hetman, R, Dudley, MW, Zeng, J, Nickner, C, Xiong, H, Komarnitsky, P, Shepherd, SP, Hurwitz, H, and Lenz, H-J. "A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours." April 2018.  Full Text
    • Loree, JM, Strickler, JH, Pereira, AAL, Lam, M, Raghav, KPS, Morris, VK, Menter, D, Banks, K, Nagy, RJ, Raymond, V, Overman, MJ, Talasaz, A, Lanman, RB, and Kopetz, S. "Serial monitoring of ctDNA to highlight mutation profiles in colorectal cancer." : American Society of Clinical Oncology (ASCO), February 2018.  Full Text
    • Angevin, E, Strickler, J, Weekes, C, Heist, R, Morgensztern, D, Fan, X, Olyaie, O, Motwani, M, Afar, D, Naumovski, L, and Kelly, K. "First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC)." January 2017.  Link to Item
    • Bendell, J, Eckhardt, GS, Hochster, HS, Morris, VK, Strickler, J, Kapoun, AM, Wang, M, Xu, L, McGuire, K, Dupont, J, Faoro, L, and Munster, P. "Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC)." December 2016.  Full Text
    • Angevin, E, Kelly, K, Heist, R, Morgensztern, D, Weekes, C, Bauer, T, Ramanathan, R, Nemunaitis, J, Fan, X, Olyaie, O, Parikh, A, Reilly, E, Afar, D, Naumovski, L, and Strickler, J. "First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors." October 2016.  Full Text
    • Ryan, DP, Murphy, J, Mahalingam, D, Strickler, J, Stein, S, Sirard, C, Landau, S, and Bendell, J. "Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)." June 2016.  Link to Item
    • Clarke, JM, Blobe, GC, Strickler, JH, Uronis, HE, Zafar, Y, Morse, M, Dropkin, E, Howard, L, O'Neill, M, Rushing, CN, Niedzwiecki, D, Watson, H, Arrowood, C, and Hurwitz, H. "Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL)." May 20, 2016.  Full Text  Link to Item
    • Strickler, JH, Rushing, CN, Uronis, HE, Morse, M, Blobe, GC, Zafar, Y, Hsu, SD, Arrowood, C, Ley, SH, Dropkin, E, Niedzwiecki, D, and Hurwitz, H. "Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC)." May 20, 2016.  Full Text  Link to Item
    • Strickler, JH, Rangwala, FA, Rushing, C, Niedzwiecki, D, Altomare, I, Uronis, HE, Hsu, SD, Zafar, Y, Morse, M, Chang, DZ, Wells, JL, Blackwell, KL, Marcom, PK, Webb, AR, Dropkin, E, Arrowood, C, and Hurwitz, H. "X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC)." February 2016.  Full Text
    • Zhang, T, Boominathan, R, Foulk, B, Connelly, MC, Rao, C, Kemeny, G, Strickler, JH, Abbruzzese, JL, Harrison, MR, George, DJ, Hurwitz, H, Garcia-Blanco, MA, and Armstrong, AJ. "Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies." May 20, 2015.  Link to Item
    • Kang, Y-K, LoRusso, P, Salgia, R, Yen, C-J, Lin, C-C, Ramanathan, RK, Kaminker, P, Sokolova, I, Bhathena, A, Wang, L, Naumovski, L, and Strickler, JH. "Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC)." January 20, 2015.  Full Text
    • O'Reilly, EM, Smith, LS, Bendell, JC, Strickler, JH, Zalupski, M, Gluck, W, Kapoun, A, Yen, W-C, Xu, L, Hill, D, Zhou, L, Dupont, J, and Cohn, AL. "Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)." : American Society of Clinical Oncology (ASCO), January 20, 2015.  Full Text
    • Kapoun, A, O'Reilly, E, Cohn, A, Bendell, JC, Smith, L, Strickler, JH, Gluck, W, Liu, YW, Wallace, B, Tam, R, Cancilla, B, Brunner, A, Hill, D, Zhou, L, Dupont, J, Zhang, C, and Wang, M. "465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)." : Elsevier BV, November 2014.  Full Text
    • Strickler, JH, LoRusso, P, Yen, C-J, Lin, C-C, Kang, Y-K, Kaminker, P, Ansell, P, Bhathena, A, Wong, S, Dudley, MW, Naumovski, L, and Ramanathan, RK. "Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors." May 20, 2014.  Link to Item
    • Strickler, JH, McCall, S, Nixon, AB, Pang, H, Rushing, C, Arrowood, C, Haley, S, Meadows, K, and Hurwitz, H. "Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors." May 20, 2013.  Link to Item
    • Hurwitz, H, Pitot, H, Strickler, J, Sorensen, JM, Leopold, L, Brill, J, and Smith, DC. "Preliminary Report of a First-in-human, Open-label, Multicenter, Phase I Study of AT-406 (Debio 1143), an Oral Small Molecule Multi-IAP Inhibitor, in Solid Tumors and Lymphomas." November 2012.  Full Text  Link to Item
    • Kollmannsberger, CK, Hurwitz, H, Cleary, JM, Strickler, JH, Drouin, MA, Juretic, M, Hunt, W, Reid, GK, Maroun, CR, Bonfils, C, Wang, J, Karam, A, Besterman, JM, Mehran, M, and Shapiro, G. "MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study." May 20, 2012.  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.